Nanexa Beheer

Beheer criteriumcontroles 4/4

De CEO Nanexa is David Westberg, benoemd in Jan2015, heeft een ambtstermijn van 9.83 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 2.85M, bestaande uit 78.4% salaris en 21.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.27% van de aandelen van het bedrijf, ter waarde € 41.05K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.8 jaar en 3.5 jaar.

Belangrijke informatie

David Westberg

Algemeen directeur

SEK 2.8m

Totale compensatie

Percentage CEO-salaris	78.4%
Dienstverband CEO	9.8yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	9.8yrs
Gemiddelde ambtstermijn bestuur	3.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is David Westberg's beloning veranderd ten opzichte van Nanexa's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-SEK 67m
Mar 31 2024	n/a	n/a	-SEK 71m
Dec 31 2023	SEK 3m	SEK 2m	-SEK 76m
Sep 30 2023	n/a	n/a	-SEK 43m
Jun 30 2023	n/a	n/a	-SEK 49m
Mar 31 2023	n/a	n/a	-SEK 55m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 59m
Sep 30 2022	n/a	n/a	-SEK 54m
Jun 30 2022	n/a	n/a	-SEK 50m
Mar 31 2022	n/a	n/a	-SEK 42m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 36m
Sep 30 2021	n/a	n/a	-SEK 31m
Jun 30 2021	n/a	n/a	-SEK 27m
Mar 31 2021	n/a	n/a	-SEK 25m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 22m
Sep 30 2020	n/a	n/a	-SEK 19m
Jun 30 2020	n/a	n/a	-SEK 18m
Mar 31 2020	n/a	n/a	-SEK 13m
Dec 31 2019	SEK 2m	SEK 1m	-SEK 13m
Sep 30 2019	n/a	n/a	-SEK 12m
Jun 30 2019	n/a	n/a	-SEK 11m
Mar 31 2019	n/a	n/a	-SEK 12m
Dec 31 2018	SEK 2m	SEK 1m	-SEK 11m
Sep 30 2018	n/a	n/a	-SEK 9m
Jun 30 2018	n/a	n/a	-SEK 9m
Mar 31 2018	n/a	n/a	-SEK 8m
Dec 31 2017	SEK 1m	SEK 1m	-SEK 8m

Compensatie versus markt: De totale vergoeding ($USD 265.45K ) David } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 490.17K ).

Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

David Westberg (64 yo)

9.8yrs

Tenure

SEK 2,847,000

Compensatie

Mr. David Westberg has been the Chief Executive Officer at Nanexa AB (publ) since 2015. Mr. Westberg serves as an Independent Director at Lipigon Pharmaceuticals AB (publ) since 2023. Mr. Westberg has expe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Westberg	Chief Executive Officer	9.8yrs	SEK 2.85m	0.27% € 41.0k
Marten Rooth	Co-Founder	15.8yrs	geen gegevens	0.33% € 48.9k
Anders Johansson	Co-Founder & Head of Intellectual Property	15.8yrs	SEK 996.00k	0.30% € 45.4k
Cecilia Danckwardt-Lilliestrom	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Mikael Asp	Head of QA & Expert Sakkunnig	4.4yrs	geen gegevens	0.0027% € 400.7
Joel Hellrup	Head of Pharmaceutical R&D	no data	geen gegevens	0.0052% € 774.3

9.8yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 40M is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Birgit Norinder	Independent Director	3.5yrs	SEK 180.00k	0.044% € 6.6k
Goran Ando	Independent Chairman of the Board	4.8yrs	SEK 260.00k	0.77% € 115.0k
Robert Gale	Member of Advisory Board - NEX-18	no data	geen gegevens	geen gegevens
Eva Nilsagard	Independent Director	3.5yrs	SEK 230.00k	0.13% € 19.9k
Magnus Westgren	Independent Director	9.8yrs	SEK 130.00k	0.19% € 28.1k
Axel Glasmacher	Member of Advisory Board - NEX-18 & NEX-20	no data	geen gegevens	geen gegevens
Richard Davis	Independent Director	2.4yrs	SEK 130.00k	geen gegevens
Kirsten Gronbaek	Member of Advisory Board - NEX-18	no data	geen gegevens	geen gegevens
Uwe Platzbecker	Member of Advisory Board - NEX-18	no data	geen gegevens	geen gegevens
Magnus Tobiasson	Member of Advisory Board - NEX-18	no data	geen gegevens	geen gegevens
Jose Miguel Diaz	Member of Advisory Board - NEX-18	no data	geen gegevens	geen gegevens
Xavier Leleu	Member of Advisory Board - NEX-20	no data	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 40M wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Nanexa Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

Less than half of directors are independent

Recent updates

Nanexa AB (Publ) Completes Phase I Trial of NEX-22 in Type 2 Diabetes

New minor risk - Revenue size

Nanexa AB (Publ) Announces That the First Patient in the Third Dose Group with Their Long-Acting Depot Formulation of the Glp-1 Analog Liraglutide Has Been Dosed

New minor risk - Profitability

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.16 loss in 2Q 2023)

Nanexa's Phase I Trial of NEX-22 in Type 2- Diabetes Progresses with Next Dose Group According to Plan

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (Publ) Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes

New major risk - Financial position

Nanexa AB Receives Approval for NEX-22 Clinical Study

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.14 loss in 1Q 2023)

Nanexa AB (publ) Announces Approval of Clinical Trial Application for NEX-22 Study Delayed

New major risk - Shareholder dilution

Full year 2023 earnings released: kr1.09 loss per share (vs kr1.16 loss in FY 2022)

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA

Third quarter 2023 earnings released: kr0.11 loss per share (vs kr0.24 loss in 3Q 2022)

Nanexa AB Completes Clinical Phase I Study with NEX-20

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

First quarter 2023 earnings released: kr0.14 loss per share (vs kr0.24 loss in 1Q 2022)

Nanexa AB (publ) to Report Q1, 2023 Results on May 04, 2023

Full year 2022 earnings released: kr1.16 loss per share (vs kr1.01 loss in FY 2021)

Nanexa AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Nanexa Starts the Phase 1 Study of NEX-20 According to Plan

No longer forecast to breakeven

Nanexa Receives Approval to Start Clinical Trial with NEX-20

Third quarter 2022 earnings released: kr0.24 loss per share (vs kr0.18 loss in 3Q 2021)

Nanexa AB (Publ) and Vitrivax, Inc Reach Agreement in Principle

Nanexa AB (Publ) Launches NEX-22 Product Project to Address Huge Market

Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.33 loss in 2Q 2021)

Nanexa AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Nanexa AB (publ) Receives Extended GMP-Certificate for the New Pilot Plant

Less than half of directors are independent

Nanexa AB (publ), Annual General Meeting, Jun 09, 2022

Nanexa Receives Grant from VINNOVA for Study with Monoclonal Antibodies

Forecast to breakeven in 2023

First quarter 2022 earnings released: kr0.24 loss per share (vs kr0.29 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nanexa AB Announces That the Company's Preclinical Investigation

High number of new directors

Nanexa Announces Inclusion of Patients in its Phase I Study with NEX-18

Second quarter 2021 earnings released

Forecast to breakeven in 2023

High number of new directors

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.22 loss in 1Q 2020)

Nanexa Appoints Jonas Fransson as Head of Pharmaceutical Development

Full year 2020 earnings released: kr1.09 loss per share (vs kr0.88 loss in FY 2019)

Nanexa AB to Report Q1, 2021 Results on May 06, 2021

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd